METIS is a B-corp* whose mission is to develop scientific knowledge about cancer and make new drugs available based on precision medicine
It was born from a deep and renowned knowledge of the MET oncogene, acquired over thirty years by Prof. P.M. Comoglio and his “team”, at the Candiolo Cancer Institute – IRCC
Possesses a significant patent portfolio
The lead, “hOA-DN30“, is a potent anticancer drug. It is an anti-MET antibody, optimized by genetic engineering (“fully humanized”, “single-armed”). The antibody is characterized by a unique mechanism of action, extremely effective, and virtually free of toxicity.
*A B-Corp is an entity that voluntarily submits to the highest standards of purpose, responsibility, and transparency, to go beyond profit, maximizing the positive impact on society, the entire human race, and the environment (as governed by Article 1 of Law No. 208 of 28 December 2015)
The Club degli Investitori is an entrepreneur association investing in start-ups and small, innovative businesses with high growth potential, in return for an equity stake. Members of the Club are forward-looking investors, on the constant lookout for innovative projects.
Investing through the Club means much more than the financial contribution: it means the involvement of a group of invaluable network of contacts and experience. The Club degli Investitori is based in Turin and has more than 150 members. Accrual of new members is only by appointment.
Italian Angels for Biotech (“IAB”) was founded in mid-2015, originating from the idea of a group of successful life sciences entrepreneurs.
IAB is an association made by a group of investors focused on Life Sciences. Members include successful entrepreneurs, prominent executives, advisors, physicians and scientists. A number of IAB members has been among the founders and/or senior executives of companies within the healthcare area.